67 filings
Page 2 of 4
8-K
77wie4m5 ps6dw0kk7
10 Aug 17
PhaseRx Reports Second Quarter 2017 Financial Results and Provides Corporate Update
12:00am
FWP
5dy 5kfp7c
10 Jul 17
Free writing prospectus
12:00am
8-K
udkxaa
26 May 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
6nuj7ric
12 May 17
PhaseRx Reports First Quarter 2017 Financial Results and Provides Corporate Update
12:00am
DEF 14A
zcm3bt4vf750
13 Apr 17
Definitive proxy
12:00am
S-8
b3a48m01qpe zk7i9
27 Mar 17
Registration of securities for employees
12:00am
8-K
ufp55
27 Mar 17
PhaseRx Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
12:00am
10-K
or3lbjf
27 Mar 17
Annual report
12:00am
8-K
9rcdlp6et0i2gjb0v86a
8 Mar 17
Regulation FD Disclosure
12:00am
8-K
forbubjd
6 Mar 17
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
4ibwa
28 Nov 16
PhaseRx Receives Orphan Drug Designation from FDA for PRX-OTC for the Treatment of Ornithine Transcarbamylase Deficiency
12:00am
8-K
9q525a9j2egqfmu2
8 Nov 16
Regulation FD Disclosure
12:00am
8-K
yfm6t4d6mx47yjvm1p
7 Nov 16
PhaseRx Reports Third Quarter 2016 Financial Results and Provides Corporate Update
12:00am
8-K
5ljq295z3roo9
24 Aug 16
Departure of Directors or Certain Officers
12:00am
S-8
onmc051
12 Aug 16
Registration of securities for employees
12:00am
10-Q
qco8k6jcu0adrfvlgz8
2 Aug 16
Quarterly report
12:00am